The Life Sciences team advised CRISPR Therapeutics (Nasdaq: CRSP) on its investment agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics’ 30-day volume-weighted average price. The financing is expected to close on or about February 27, 2024, subject to customary closing conditions. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a leading healthcare specialist investor.
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines.
The Goodwin team was led by Rob Puopolo and Marishka DeToy.
For additional details on the agreement, please read the press release.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.